Advancing Drug Repositioning Through Systems Approaches and Data Integration

DReNIn_O “A high-level ontology for drug repositioning” Joseph Mullen ICOS, School of Computing Science, Newcastle University • Prof. Anil Wipat • Dr. Simon Cockell • Peter Woollard

Drug Discovery “Increasing in cost and reducing in productivity” • 2005-2009 22 drugs / year • Low hanging fruit has been picked • State of R&D needs to change • Precision medicine or drug repositioning

Drug Repositioning “Identifying new uses for existing drugs”

Drug Repositioning “Identifying new uses for existing drugs” • Marketed examples found due to ‘luck’ • E.g. sildenafil (PAH -> ED) • Need for more systematic approaches • Such as systems approaches

Systems Approach “Enables an holistic view of a drugs interactions” TARGET DISEASE DRUG Involved in binds to has indication

Systems Approach “Allows for a holistic view of a drugs interactions” Clinical Trial MoA Pathway GO Small Molecule Rare Disease Common Disease Bio Tech TARGET DISEASE DRUG Drug Combination Involved in binds to Nutraceutical has indication Gene Protein Binding site Alternative Transcript Isoform

DReNIn_O “A high-level ontology for drug repositioning” https://bitbucket.org/ncl-intbio/drenin_ontology

DReNIn “An RDF drug repositioning dataset with a SPARQL endpoint” http://drenin.ncl.ac.uk

To Conclude • DReNIn_O high level ontology • Systems approaches to drug repositioning • Data integration • Data mining • Infer novel uses for existing drugs

Acknowledgements Prof. Anil Wipat and Dr. Simon Cockell from Newcastle University. Dr. Philipe Sanseau, Peter Woollard and Hannah Tipney from GSK. We thank the EPSRC and GSK for funding of the CASE studentship.

j.mullen@ncl.ac.uk QUESTIONS?

Advancing Drug Repositioning Through Systems Approaches and Data Integration